Allogeneic hematopoietic cell transplantation (HCT) is the only known curative modality for patients with Philadelphia chromosome positive acute lymphoblastic leukemia(Ph+ ALL).
INTRODUCTION
In patients with acute lymphoblastic leukemia, the frequency of the Philadelphia chromosome or translocation(9;22) increases with age and is detected in ~ 5% of children and in ~ 30% in adults 1 . Despite high response rates to induction chemotherapy, relapse occurs frequently resulting in a 5 year OS of only 0-20%. The only known curative therapy for patients with Ph+ ALL is allogeneic hematopoietic cell transplantation (HCT) with this treatment conferring the most benefit when patients are transplanted early in the course of their disease [2] [3] [4] [5] .
Twenty years ago, we reported the first series of ten patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who were treated with high dose conditioning regimens followed by hematopoietic cell transplantation (HCT) from histocompatible siblings 6 . Six of the ten patients became long term disease free survivors 7 .
In the same year, 1987, we described a new preparatory regimen consisting of fractionated total body irradiation(FTBI) and VP16 8 . This regimen was found to be a potent combination for patients with acute leukemia and other hematologic malignancies [9] [10] [11] [12] . Later, the regimen was enhanced by adding cyclophosphamide to FTBI and VP-16, especially for patients with advanced stage hematologic malignancies 13 . The current report details the experience in 79 patients with Ph+ ALL who were treated during the past two decades at the City of Hope National Medical Center and at Stanford University Medical Center.
PATIENTS AND METHODS

Patient Characteristics
The databases from the Stanford Blood and Marrow Transplantation Program and City of Hope National Medical Center were screened for patients with the diagnosis of Philadelphia chromosome positive acute lymphoblastic leukemia. Pediatric(n=10) and adult(n=69) patients who underwent allogeneic HCT from 1985 to 2005 for the diagnosis of Ph+ ALL were identified for the purpose of this analysis. All patients had B-lineage ALL and HLAmatched siblings were the hematopoietic cell donors for all patients. The patient characteristics are listed in Table I . Seventy nine patients comprised this analysis and ranged in age from 2-57 years (median, 36 years). Thirty two patients (40%) also had other chromosomal abnormalities in the addition to translocation (9;22) . The median WBC at 
Cytogenetic Analysis and fluorescence in situ hybridization (FISH) analyses
Karyotype analysis on pretreatment and follow-up bone marrow and peripheral blood samples were performed using standard methods. Dual-color FISH analysis were performed on bone marrow samples as per the manufacturer's instructions (Abbott/Vysis, Downer's Grove, IL).
Polymerase Chain Reaction (PCR)
The presence of bcr-abl mRNA by PCR was measured before and after HCT in most patients although the timepoints of study were not consistent among patients. PCR analyses were performed as previously described with some patients expressing the p190 variant and other expressing the p210 form. Additionally, the presence of bcr-abl RNA copies was measured either qualitatively and/or quantitatively among some patients.
Conditioning Regimen and Graft vs Host Disease Prophylaxis
All patients underwent high dose conditioning that included fractionated total body irradiation prior to HCT 14, 15 . As listed in Table I , the majority of patients (85%) received the preparatory regimen of fractionated total body irradiation (FTBI) 1320 cGy delivered in 11
For personal use only. on January 3, 2018. by guest www.bloodjournal.org From fractions over 4 days followed by etoposide (VP16) at 60 mg/kg administered as a single infusion over four hours. Eleven patients (14%) received the combination of FTBI/VP16/cyclophosphamide with the cyclophosphamide(CY) dose of 60 mg/kg and one patient received FTBI/VP16/busulfan for the purpose omitting CY due to the patient's history of severe hemorrhagic cystitis from previous CY exposure. Forty three patients (54%) received bone marrow as the hematopoietic cell source with 36 patients (46%) receiving filgrastim-mobilized peripheral blood hematopoietic cells. The grafts were not T cell depleted.
Various regimens were administered for graft vs host disease(GVHD) prophylaxis as per institutional trials conducted during the time period of analysis. The most commonly used regimens consisted of cyclosporine and methotrexate on days +1, +3, +6 and +11(47%) followed by cyclosporine and prednisone(29%). Table I lists all regimens administered.
Statistical Analysis
Survival estimates were calculated based on the product-limit method, and 95% confidence intervals were calculated using the logit transformation and the Greenwood variance estimate 16 . Differences between survival curves were assessed by the Log Rank test. The significance of demographic/treatment features collected from HCT recipients was assessed using survival analysis and univariate Cox regression analysis 17 . The list of features included was determined from a literature review that identified factors found to be associated with survival and disease relapse in patients treated with allogeneic HCT. The values/levels of each variable, whether continuous or categorical, were based on findings published by large cooperative group and multi-centered studies. Statistical significance was defined at the p ≤ 0.05 level.
Results
Overall Survival and Event Free Survival
The median followup for all patients was 75 months (range, 14-245 months). When analyzed by disease status, the median followup for the CR1 patients and >CR1 patients were 75 months (14-180 months) and 127 months (range 16-245 months), respectively. Disease status at the time of HCT had a significant impact on both OS and EFS. The estimated 10
For personal use only. on January 3, 2018. by guest www.bloodjournal.org From year OS for the CR1 patients and >CR1 patients were 54% and 29% respectively (p=0.01), (see Figure 1a ) and for EFS were 48% and 26%, respectively (p=0.02). As the time of accrual spanned over 20 years, OS was examined by decade of HCT (1985 HCT ( -1995 HCT ( , n=35 vs 1996 HCT ( -2005 ) with no significant difference seen among these two time periods(5 yr OS: 43% vs 46%, p=0.74, respectively), see Figure 1b . Additionally, the outcomes of the 10 pediatric/adolescent patients who were < 18 years at the time of HCT were compared to the 69 adult patients.
OS and relapse incidence was not found to be significantly different between these two groups(10 year OS: 44% for both groups, p=0.91, and 10 year relapse incidence was 42% vs 34% , p=0.61, respectively).
The impact of imatinib on transplant outcomes was also assessed. Of the seventeen patients who received imatinib prior to HCT, fifteen patients entered HCT in CR1. It was not possible to accurately assess the impact of imatinib on transplant outcomes compared to the rest of the cohort as the median followup of the 17 imatinib-treated patients was only 5 months (range 1-53 months) and the comparative sample sizes are unbalanced. However, of these 17 patients, six patients are alive and in continuous CR. Of the 11 patients who have expired, one patient died from relapse and 10 patients succumbed from NRM-related causes.
By univariate analysis, pre-HCT factors found to affect both OS and EFS were WBC at diagnosis (<30,000/µl vs >30,000/µl, p=0.03 and 0.04, respectively), disease status at HCT (CR1 vs > CR1, p=0.01 and 0.02, respectively) and development of grade 2-4 acute GVHD(p=0.04 and 0.01 respectively), see Table II . When tested by multivariate analysis, WBC at diagnosis and disease status remained significant for both OS and EFS while grade 2-4 acute GVHD was significant for DFS with a trend seen with OS, see Table III . The presence of chromosomal abnormalities in addition to t(9;22) did not significantly impact survival outcomes.
Graft vs Host Disease and Hematopoietic Cell Source
Acute GVHD was observed in 39 (49%) patients with grade 2-4 acute GVHD occurring in 28 (35%) patients. Twenty six of the 68 patients evaluable developed chronic GVHD with extensive manifestations seen in 9 of these patients. As mentioned previously, the presence of acute GVHD was an adverse factor for both OS and EFS. The development of chronic GVHD did not significantly affect survival or relapse.
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Relapse and Causes of Death
A total of 44 patients have expired. The cumulative incidence of non-relapse mortality for all patients was 35% with infection (n=10) and cardiopulmonary complications (n=8) representing the most frequent causes of NRM. The other causes of nonrelapse death included acute GVHD(n=5), chronic GVHD(n=3), diabetes mellitus(n=1) and one patient died in remission from an unknown cause. All deaths due to NRM occurred within 3 years following HCT with the exception of one patient who died ~18 years after HCT from diabetes-related complications. When analyzed by disease status at HCT, NRM was significantly higher among the >CR1 vs the CR1 patients, 54% vs 31% (p=0.05) respectively, see Figure 3a . The inferior OS and EFS for the >CR1 patients was attributed to the higher NRM. The development of grade 2-4 acute GVHD also significantly increased NRM (p=0.01). NRM did not significantly differ when analyzed by decade of HCT. The 5 year NRM was 36% for the patients transplanted between 1985 -1995 and also 36% between 1996 -2005,(p=0.93).
Sixteen patients have expired from relapse yielding a relapse mortality of 20%. The median time to relapse for the CR1 patients was 12 months (range, 1-27 months) and for the >CR1 patients was 9 months (range, 3-19 months). The latest observed relapse in our entire cohort was seen at 27 months post-HCT. For patients in CR1 and >CR1, the relapse rates were 28% and 41% (p=0.17), respectively, see Figure 3b . There was no difference in 10 year relapse incidence between the pediatric and adult subgroups (42% vs 34%, p=0.61, respectively). By univariate analysis, hematopoietic cell source, the presence of acute or chronic GVHD, WBC at diagnosis or additional cytogenetic abnormalities did not affect relapse incidences, see Table II .
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Cytogenetic and Molecular Analyses
By cytogenetic analyses, all patients were Philadelphia chromosome positive at diagnosis. Additional clonal abnormalities were seen in 32 patients at diagnosis but this finding did not significantly affect outcomes. All long term survivors remain in a complete cytogenetic remission by sequential analyses.
Molecular diagnoses of either minor or major bcr-abl transcripts were performed in most but not all patients. Over the 20 year course of our study, various molecular techniques were introduced ranging from qualitative PCR to highly specific quantitative PCR. PCR data were available in 57 patients. Thirty-one patients were PCR negative and 26 patients were PCR positive at the time of HCT. When analyzed by the presence or absence of PCR positivity for the bcr-abl fusion transcript, PCR status at the time of HCT was not predictive of outcome. Comparing the outcomes of the PCR negative and PCR positive patients, the 10 year OS, EFS and relapse incidences were 43% vs 46%, p=0.99, 40% vs 39%, p=0.69 and 30% vs 43%, p=0.37, respectively. All long term survivors remain PCR negative except for one patient who experienced a molecular relapse. This particular patient has responded to imatinib and currently is in continued molecular remission.
Discussion
Although patients with Ph+ ALL typically respond to upfront combination chemotherapy, their remissions are rarely durable. The median EFS following combination chemotherapy is only ~ 8 months with a 5 year OS of 0-20% 5, 18 . Due to these dismal outcomes, allogeneic HCT has been considered the optimal treatment after induction chemotherapy for patients with a suitable donor. Our report summarizes the outcomes of 79 patients with Ph+ ALL who underwent allogeneic HCT at Stanford University and the City of Hope National Medical Center. This retrospective review is the largest reported uniform series to date of Ph+ ALL patients who received an FTBI/VP16 containing regimen followed by allografting from matched sibling donors and also contains the longest median followup time compared to all other published series.
Despite the inherently poor prognosis of patients with Philadelphia chromosomepositive ALL, our results demonstrate that many patients can be cured if allogeneic HCT is Philadelphia chromosome (OS and EFS of 41% and 36% , respectively, p<.001 for both).
These outcomes included patients treated with either transplant or conventional chemotherapy.
Similar to our study, registry data from the French Societe Francaise de Greffe de Moelle -Therapie Cellulaire(SFGM-TC) of 121 Ph+ ALL patients who received an allogeneic HCT with either matched related or unrelated donors also confirmed that remission status was a highly significant favorable prognostic factor for survival 4 . For patients in CR1 and >CR1, the 2 year OS was 50% and 17% (p<0.0001) respectively. The CR1 patients also experienced a significantly lower relapse rate(p=0.02) which was not observed in our study. But similar to our results, the SFGM-TC study revealed a trend for improved OS for patients with a lower WBC (<25,000/µl vs >25,000/µl ) at the time of diagnosis(p=0.07). We also found that a high WBC (>30,000/µl) at diagnosis was an adverse factor for both OS(p=0.03) and EFS(p=0.04) in univariate analysis with results remaining significant in a multivariate test. Also observed in our series, the development of grade 2-4 acute GVHD was associated with a significantly higher NRM which negatively impacted OS and DFS. However, in contrast to our study, the SGFM-TC report found that acute GVHD was a favorable factor in terms of decreasing relapse risk (p=0.02). When separated by disease status in our study, NRM was notably higher in the >CR1 compared to CR1 patients (54% vs 31%, p=0.03). As the relapse rate did not significantly differ by remission status in our series, the higher NRM in the >CR1 group accounted for the inferior OS and EFS.
Fifty four percent of patients in the present study received BM as the source of HC which primarily reflects the change in practice within the field of HCT as virtually all grafts from 1999 consisted of peripheral blood as the HC source. The incidence of chronic GVHD was nearly twice as high in the PB recipients (29% vs 57%, p=0.01) although acute GVHD was not different confirming the findings seen in randomized studies comparing recipient outcomes after PB and BM HCT 22,23 . Interestingly, the higher incidence of chronic GVHD among the PB recipients did not decrease relapse risk as reported in other studies.
Relapse incidence did not vary by remission status which may speak for the potent antileukemic effect of high dose VP16 combined with FTBI. Our relapse incidence of 20% among 79 patients compares favorably or is superior compared to similar published studies, especially in light of our long followup time. The median time to relapse was less than 12
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Approximately 85% of our patients received the conditioning regimen of FTBI with high dose VP16 which we first introduced as a new preparative regimen in 1987 6 . This regimen and the FTBI/high dose cyclophosphamide regimen are currently the two most commonly offered regimens in the high dose allogeneic HCT setting for acute leukemia patients. Interestingly, a recently published registry report compared the outcomes of 298 patients with ALL including patients with Ph+ALL in CR1 or CR2 undergoing allogeneic HCT with matched related donors 11 . No differences in survival or relapse were observed in the CR1 patients but a significant advantage was seen in substituting etoposide for cyclophosphamide in the CR2 patients in terms of survival, relapse and mortality which again emphasizes the antileukemic efficacy of high dose VP16.
Recent reports have detailed the feasibility and efficacy of adding imatinib to conventional chemotherapy to increase the rate of CR for newly diagnosed Ph+ ALL patients [24] [25] [26] [27] . Imatinib, which inhibits the breakpoint cluster region-Abelson (bcr-abl) tyrosine kinase, has been shown to induce responses in Ph+ ALL patients including patients who have previously failed allogeneic HCT [28] [29] [30] . Achievement of CR after upfront combination chemotherapy is of tantamount importance since outcomes after allogeneic HCT are strongly affected by disease status at the time of HCT. When added to combination chemotherapy, imatinib has been shown to increase and prolong CR rates and to confer a survival advantage whether or not patients proceeded to allogeneic HCT compared to historical controls [24] [25] [26] [27] . Increasing the rate and duration of CR also improves the patient's candidacy for HCT. Our analysis commenced over a 20 year time period beginning in 1985 and thus only seventeen patients (22%) in our series received imatinib with combination chemotherapy prior to HCT. Fifteen of these 17 patients obtained a complete remission prior to HCT. However, due to this small sample size and short median followup of this subset of patients, it is not possible to accurately discern the true impact of pre-HCT imatinib in our study. The use of imatinib post-HCT as maintenance therapy is also under investigation and perhaps will also increase the efficacy of HCT 31 .
In summary, our results show that for Ph+ALL patients with a matched sibling donor, remission status at the time of HCT is one of the most important prognostic factors for Published results show no difference in outcome by donor type and thus, a search for an unrelated donor should commence immediately if a matched related donor is not available.
Fortunately, with the increasing availability of allogeneic HCT due to the rising number of alternative donors and with the increasing use of tyrosine kinase inhibitors before and after HCT, the cure rate for patients with Ph+ ALL will hopefully improve. 
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